Recent Advances in Locoregional Therapy of Hepatocellular Carcinoma

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second most common oncological reason for death. Liver resection and transplantation are considered the only potential cure options for HCC. The majority of patients, however, are late in presentation and, therefore, are considered non-suitable for surgery at the time of diagnosis. Locoregional therapies are becoming integral to its management along with systemic therapies. This review discusses the role and the advances of locoregional therapies in HCC management. ABSTRACT: Hepatocellular carcinoma (HCC) is responsible for 90% of primary hepatic cancer cases, and its incidence with associated morbidity and mortality is growing worldwide. In recent decades, there has been a revolution in HCC treatment. There are three main types of locoregional therapy: radiofrequency ablation, transarterial chemoembolisation, and transarterial radioembolisation. This article summarises recent advances in locoregional methods.